1. Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М.: Медицина, 2000; 130.
2. Строков И.А., Аметов А.С., Козлова Н.А., Галеев И.В. Клиника диабетической невропатии. Рус. мед. журн. 1998; 12: 797–801.
3. Аметов А.С., Строков И.А. Диабетическая полинейропатия: настоящее и будущее. Рос. мед. вести. 2001; 6 (1): 35–40.
4. Ziegler D. Tretment of diabetic neuropathy and neuropathic pain. Diabetes Care 2008; 31: S255–61.
5. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561–8.
6. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compare with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53.
8. Антонова К.В., Недосугова Л.В., Балаболкин М.И. и др. Влияние компенсации углеводного обмена на свободнорадикальное окисление липопротеидов низкой плотности и активности ферментативной антиоксидантной системы при сахарном диабете типа 2. Пробл. эндокринол. 2003; 49 (2): 1–4.
9. Ziegler D. Glycemic control. In "Textbook of diabetic neuropathy". Ed. F.A.Gries et al. Thieme 2003; 91–6.
10. Прихожан В.М. Поражение нервной системы при сахарном диабете. М.: Медицина, 1981; 220.
11. Cameron NF, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 (Suppl. 2): S31–S37.
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.
13. Hammes HP, Du X, Edelstein D et al Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Med 2003; 9: 1–6.
14. Зотова Е.В., Чистяков Д.А., Савостьянов К.В. и др. Изучение ассоциации полиморфных маркеров Ala(-9) Val гена SOD2 и Arg213Gly гена SOD3 с диабетической полинейропатией у больных сахарным диабетом типа 1. Мол. биол. 2003; 3: 345–8.
15. Лаврова И.Н. Роль сосудистых и метаболических нарушений в развитии диабетической полиневропатии. Клинико-генетическое исследование. Автореф. дис. … кан. мед. наук. М., 2005.
16. Nosikov VV, Strokov IA, Nikitin AG et al. Poly (ADP-ribose) polymerase-1 gene (PARP1) involved in the genetic susceptibility to diabetic polyneuropathy in Russian patients with Type 1 diabetes mellitus. In book of abstr. 14th Annual Scientific Meeting of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB) – Regensburg, Germany, 2004; 138.
17. Strokov IA, Bursa TR, Drepa OI et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol 2003; 40: 375–9.
18. Строков И.А., Строков К.И., Солуянова Т.В. От тиамина к бенфотиамину: современные подходы в лечении диабетической полиневропатии. Фарматека. 2006; 7: 57–61.
19. Строков И.А., Моргоева Ф.Э., Строков К.И. Терапевтическая коррекция диабетической полиневропатии и энцефалопатии Актовегином. Рус. мед. журн. 2006; 9: 698–703.
20. Строков И.А., Ишунина А.М., Новосадова М.В. и др. Антиоксидантная терапия диабетической полиневропатии и ретинопатии у больных сахарным диабетом типа 2: эффективность танакана. Неврол. журн. 2003; 2: 43–9.
21. Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diaberic Medicine 2004; 21: 114–21.
22. Reed LJ. Multienzyme complex. Acc Chem Res 1974; 7: 40–6.
23. Packer L, Witt EH, Tritschler H. Alfa-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227–50.
24. Скляр И.А., Воробьева О.В., Шаряпова Р.Б. и др. Тиоктацид в лечении алкогольной полиневропатии. Леч. нерв. бол. 2001; 2 (2): 39–41.
25. Яковенко Э.П., Яковенко А.В., Григорьев П.Я. и др. Роль альфа-липоевой кислоты в терапии метаболических заболеваний печени. Фарматека. 2005; 99 (3): 25–9.
26. Ziegler D, Reljanovic M, Mehnert H et al. α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107: 421–30.
27. Borenshtein D, Ofri R, Werman M et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001; 17: 44–50.
28. Melhem MF, Craven PA, Liachenko J et al. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002; 13: 108–16.
29. Nagamatsu M, Nickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160–7.
30. Ramrath S, Tritchler HJ, Eckel J. Stimulation of cardiac glucose transport by thioctic acid and insulin. Horm Metab Res 1999; 31: 632–5.
31. Stevens MJ, Obrosova I, Cao X et al. Effect of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006–15.
32. Строков И.А., Манухина Е.Б., Бахтина Л.Ю. и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. БЭБиМ. 2000; 130 (10): 437–41.
33. Borcea V, Nourooz-Zadeh J, Wolff SP et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med 1999; 22: 1495–500.
34. Haak ES, Usadel KH, Kohleisen M et al. The effect of κ-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28–34.
35. Hofmann MA, Bierhaus A, Zumbach MS et al. Insufficient glycemic control increases nuclear factor-α B binding activity in peripheral blood mononuclear cells isolated from patients with type I diabetes. Diabetes Care 1998; 21: 1310–6.
36. Hermann R, Niebch G. Human pharmacokinetics of κ-lipoic acid. In book "Lipoic acid in health and disease" (Eds. Fuchs J, Packer L, Zimmer G) – Marcel Dekker Inc N-Y. 1997; 337–60.
37. Gleiter CH, Schug BS, Hermann R et al. Influence of food intake on the bioavailability of thioctic eneantiomers. Eur J Clin Pharmacol 1996; 50: 513–4.
38. Gleiter CH, Schreeb KH, Freudenthaler S et al. Lack of interaction between thioctic acid, glibenclamide and acarbose. Br J Clin Pharmacol 1999; 48: 819–25.
39. Biewenga GP, Haenen GRM, Bast A. The role of lipoic acid in the treatment of diabetic polyneuropathy. Drug Met Rev 1997; 29: 1025–54.
40. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant a-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425–33.
41. Строков И.А., Баринов А.Н., Новосадова М.В. и др. Клинические методы оценки тяжести диабетической полиневропатии. Неврол. журн. 2000; 5: 14–9.
42. Аметов А.С., Строков И.А., Баринов А.Н. и др. Альфа-липоевая кислота в лечении симптомной диабетической полиневропатии: symptomatic diabetic neuropathy (SYDNEY) trial. Фарматека. 2004; 11 (88): 69–73.
43. Ametov AS, Barinov A, Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with κ-lipoic acid. Diabetes Care 2003; 26 (3): 770–6.
44. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy. Treat Endocrinol 2004; 3: 1–17.
45. Jorg J, Metz F, Scharafinski H. Zur medikamentosen Behandlung der diabetischen polyneuropathie mit der α-liponsaure oder vitamin B-Praparaten. Nervenarzt 1988; 9: 36–44.
46. Strokov IA, Novosadova MV, Lavrova IN et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. Abstr of the 14th Annual Scientific Meeting of the DFSG and NEURODIAB, Regensburg, Germany, September 2–5, 2004; 195.
47. Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343–8.
48. Ziegler D, Ametov A, Barinov A et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
49. Ishida Y, Ohara T, Okuno Y et al. α-Lipoic acid and insulin autoimmune syndrome. Diabetes Care 2007; 30: 2240–1.
50. Uchigata Y, Hirata Y. Insulin autoimmune syndrome. Ann Med Interne (Paris) 1999; 150: 245–53.